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Abstract
The intracellular second messenger cyclic AMP (cAMP) is degraded by phosphodiesterases (PDE). The knowledge of
individual families and subtypes of PDEs is considerable, but how the different PDEs collaborate in the cell to control a cAMP
signal is still not fully understood. In order to investigate compartmentalized cAMP signaling, we have generated a
membrane-targeted variant of the cAMP Bioluminiscence Resonance Energy Transfer (BRET) sensor CAMYEL and have
compared intracellular cAMP measurements with it to measurements with the cytosolic BRET sensor CAMYEL in HEK293
cells. With these sensors we observed a slightly higher cAMP response to adenylyl cyclase activation at the plasma
membrane compared to the cytosol, which is in accordance with earlier results from Fluorescence Resonance Energy
Transfer (FRET) sensors. We have analyzed PDE activity in fractionated lysates from HEK293 cells using selective PDE
inhibitors and have identified PDE3 and PDE10A as the major membrane-bound PDEs and PDE4 as the major cytosolic PDE.
Inhibition of membrane-bound or cytosolic PDEs can potentiate the cAMP response to adenylyl cyclase activation, but we
see no significant difference between the potentiation of the cAMP response at the plasma membrane and in cytosol when
membrane-bound and cytosolic PDEs are inhibited. When different levels of stimulation were tested, we found that PDEs 3
and 10 are mainly responsible for cAMP degradation at low intracellular cAMP concentrations, whereas PDE4 is more
important for control of cAMP at higher concentrations.
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Introduction
The second messenger adenosine 39,59-cyclic monophosphate
(cAMP) is involved in a variety of intracellular processes [1]. Most
importantly, cAMP regulates the activity of protein kinase A,
which in turn activates several downstream targets [2]. cAMP
signals are initiated by transmembrane adenylyl cyclases that
generate cAMP from ATP when activated by ligand binding to
Gs-coupled GPCRs [3]. cAMP is degraded by phosphodiesterases
(PDE) [4]. The 11 families of PDEs comprise numerous subtypes
and splice variants, differing in expression pattern, subcellular
localization, substrate affinities, and mode of regulation [5–7].
Thus, how external stimuli are processed by cells through cAMP
depends not only on receptor profile but also on the subtypes of
PDEs expressed in any given cell type.
The recent development of genetically encoded FRET sensors
for cAMP detection [8] has made direct study of cAMP regulation
in living cells possible. In cardiac myocytes, b-adrenergic stimula-
tion generates multiple microdomains of increased cAMP concen-
tration [9]. In primary cultures of hippocampal neurons, FRET
sensors have been used to study the propagation of cAMP signals
along neurites [10,11]. FRET sensors have also been used to study
cAMP compartmentalization in the much smaller HEK293 cells by
targeting FRET sensors to specific subcellular compartments such
as plasma membrane, nucleus, or mitochondria [12,13]. Both
studies observed a faster cAMP response at the plasma membrane
compared to the cytosol after adenylyl cyclase stimulation. In one of
these studies [13], but not in the other [12], the maximal cAMP
response at the plasma membrane was also significantly higher than
in the cytosol. These and other data suggest that cAMP is in many
cases compartmentalized, i.e. that cAMP concentration differs
between cellular subdomains under certain conditions. Together
with differential subcellular localization of downstream signaling
mediators such as protein kinase A isoforms, this is thought to
underlie compartmentalization of cAMP signaling [14,15]. The
mechanism for achieving cAMP compartmentalization that has
most experimental support is that the rates of cAMP degradation
differ between compartments due to subcellularly localized PDEs
[14–16].
Intracellular measurement of cAMP with FRET sensors requires
imaging of single cells. This is time-consuming and limits the
number of conditions that can be tested. A recently developed
cAMP BRET sensor makes it possible to study populations of cells
[17,18]. While the FRET sensors require excitation of the donor
molecule through an external source, the BRET sensor produces
the energy required for the donor emission with the encoded
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24392luciferase. This leads to a higher signal-to-noise ratio because no
autofluorescence is produced.
In the present study, we have generated a membrane-targeted
variant of the cAMP BRET sensor CAMYEL [17] and have
compared cAMP measurements from it to that of the cytosolic
CAMYEL in HEK293 cells. We have analyzed PDE activity in
subcellularly fractionated lysates from HEK293 cells. We found
that PDE4 dominates cAMP degradation in the cytosol, while
PDEs 3 and 10 dominate in the membrane fraction. We have
tested a range of concentrations of the direct adenylyl cyclase
activator forskolin and the GPCR ligand prostaglandin E1 (PGE1)
in combination with selective inhibitors to membrane-bound and
cytosolic PDEs. We found no evidence that the membrane-
associated and cytosolic PDEs have differential effects on membrane-
proximal and cytosolic concentrations of cAMP. When different
levels of stimulation were tested, we found that PDEs 3 and 10 are
mainly responsible for cAMP degradation at low cAMP concen-
trations whereas PDE4 is more important for controlling cAMP at
higher concentrations.
Results
Cytosolic and membrane-targeted cAMP BRET sensors
In order to measure changes of cAMP concentration in real
time in living cells we used the cAMP BRET sensors CAMYEL
[17] and PDE2-CAMYEL. CAMYEL consists of catalytically
inactive Epac1 sandwiched between the Renilla luciferase and the
yellow fluorescent protein variant Citrine (Figure 1A). The
mechanism underlying detection of cAMP by this sensor is
schematized in Figure 1B. We found that the CAMYEL sensor is
evenly distributed in the cytosol (Figure 1C and D) in agreement
with previous observations [17].
In order to also measure cAMP near the plasma membrane, a
membrane localized variant of the sensor was needed. The
PDE2A splicevariant 3 hasbeen shown to be targeted tothe plasma
membrane through myristoylation and palmitoylation of the N-
terminal region [19]. We fused the 196 N-terminal amino acids of
this splice variant to the N-terminal of the BRET sensor CAMYEL
andsogeneratedthe membranelocalizedvariant PDE2-CAMYEL.
As shown in Figure 1C and D, this cAMP BRET sensor is targeted
to the plasma membrane as predicted.
For direct comparison of cAMP responses measured with the
two sensors, it is paramount that their sensitivity to cAMP is
similar. Therefore, BRET dose-response relationship to cAMP
was tested in lysates from HEK293 cells transfected with either
CAMYEL or PDE2-CAMYEL. There was no significant difference
in the activation constants of CAMYEL and PDE2-CAMYEL
(P=0.12; Figure 2).
Cytosolic and membrane-associated PDEs in HEK293 cells
We estimated the relative contribution of different PDEs in PDE
activity assays on lysates from HEK293 cells with selective PDE
inhibitors targeting PDE1, PDE2, PDE3, PDE4 and PDE10. We
performed the PDE activity assays on separated cytosol and
membrane fractions (Figure 3) in order to test whether PDEs
localized to either membrane or cytosol have differential effects on
cAMP control. Of the PDEs tested, PDE4 was the only significant
contributor to cAMP PDE activity in the cytosolic fraction
(Figure 3A). In contrast, the membrane fraction was dominated by
PDE3 (42%) and to a smaller extent PDE10 (22%), with only a
small, but significant (13%), contribution of PDE4 (Figure 3B). In
conclusion, we found that PDE4 activity dominated in the
cytosolic fraction of HEK293 cells whereas PDEs 3 and 10
dominated in the membrane fraction.
Figure 1. Schematic overview of BRET sensors. (A) CAMYEL is comprised of cytosolic, catalytic inactive Epac1 sandwiched between Citrine-
cp229 and the Renilla luciferase (RLuc). PDE2-CAMYEL is targeted to the membrane by fusion of the N-terminal part of PDE2A3 to CAMYEL. (B)
Binding of cAMP to CAMYEL/PDE2-CAMYEL induces a conformational change in the Epac1 part resulting in a decrease of energy transfer from the
luciferase to Citrine. (C and D) Western blot and confocal images showing the distribution of CAMYEL in the cytosol and the targeting of PDE2-
CAMYEL to the membrane. Cyt, cytosolic fraction; Mem, membrane fraction.
doi:10.1371/journal.pone.0024392.g001
cAMP Control in Two Compartments in HEK293 Cells
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PGE1
Having determined which PDEs dominate in membrane and
cytosolic fractions, we next wanted to determine whether PDEs
localized to membrane or cytosol had differential effects on cAMP
concentration in these compartments. Furthermore, we tested two
different stimulation paradigms to see if they influenced compart-
mentalization and PDE control of the cAMP response: Forskolin,
which directly activates adenylyl cyclases, and prostaglandin E1
(PGE1), which activates adenylyl cyclases indirectly through
GPCR stimulation.
HEK293 cells were transfected either with the cytosolic BRET
sensor CAMYEL or the membrane-bound PDE2-CAMYEL.
Following baseline measurement, cells were stimulated with 1 mM
forskolin or 10 nM PGE1, either alone or together with a PDE4
inhibitor or a combination of PDE3 and PDE10 (PDE3/10)
inhibitors. Data from representative experiments for the different
treatments are shown in Figure 4A–F, where each point indicates
the mean 6 SEM of triplicate determinations in each experiment.
For all treatments except PDE inhibitors alone, BRET signal
decreased in response to treatment (indicating increasing cAMP
levels), reaching a plateau after 3–10 minutes.
In order to facilitate comparison of BRET responses between
experiments, relative responses were calculated by comparison of
the average response for the time period 21–30 min after addition
of drugs for each treatment to untreated cells and maximum
response in the same experiment. Mean 6 SEM relative responses
from three independent experiments are shown in Figure 4G
and H.
Addition of PDE inhibitors alone to the HEK293 cells did not
result in significant changes in the BRET signal for either sensor
(Figure 4A and B, results summarized in G and H).
The relative response to 1 mM forskolin was 8.461.9% for cells
transfected with CAMYEL and 11.464.1% for those transfected
with PDE2-CAMYEL (Figure 4C and D, results summarized in G
and H). Addition of PDE3/10 inhibitors increased the response up
to three times for both the cytosolic and membrane targeted
BRET variants (to 23.562.0% and 25.262.8%, respectively). In
contrast, PDE4 inhibition did not significantly increase the cAMP
response to 1 mM forskolin.
The relative response to 10 nM PGE1 was 32.162.9% for
CAMYEL and 32.862.2% for PDE2-CAMYEL (Figure 4E and
F, results summarized in G and H). The modulation of the
response by PDE inhibitors after stimulation with PGE1 was
different from that observed after stimulation with forskolin. Thus,
the PDE4 inhibitor augmented the response to 56.864.7% and
66.262.0% for CAMYEL and PDE2-CAMYEL, respectively,
whereas PDE3/10 inhibitors had no significant effect on PGE1-
induced cAMP increase measured with either of the BRET
sensors.
Figure 2. Characterization of the BRET sensors. cAMP dose-
response graphs showing the relative activation of CAMYEL and PDE2-
CAMYEL from HEK293 lysates. EC50 values were 8.460.7 mM and
10.660.9 mM, respectively (n=3–4).
doi:10.1371/journal.pone.0024392.g002
Figure 3. cAMP PDE activity in HEK293 cytosol and membrane fractions. Lysate from either the cytosolic fraction (A) or the membrane
fraction (B) was tested in the PDE activity with 1 mM cAMP. Selective PDE inhibitors were added alone or in combination as indicated. The results
represent the mean 6 SEM of three experiments. Compounds and concentrations used: PDE1i, 250 nM (see M&M section); PDE2i, 20 nM BAY 60-
7550; PDE3i, 400 nM cilostamide; PDE4i, 50 nM roflumilast; PDE10i, 300 nM MP-10. The ratio of total cAMP PDE activity in the cytosolic fraction and
membrane fraction compared to whole cells was 40.465.3% and 59.665.3%, respectively.
doi:10.1371/journal.pone.0024392.g003
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CAMYEL sensor and the cytosolic CAMYEL sensor for the six
different conditions tested in Figure 4 were compared, we found
no significant differences between the response measured with
PDE2-CAMYEL and that measured with CAMYEL. However,
all 6 comparisons showed a trend towards stronger response with
PDE2-CAMYEL, suggesting that membrane-proximal cAMP
levels may be slightly higher than in bulk cytosol. We saw no
difference in the time to reach half-maximal BRET response for
the two sensors for any of the treatments, including the maximal
stimulation, suggesting that the rate of cAMP increase is similar
near the plasma membrane and in the cytosol (results not shown).
In conclusion, there was a consistent trend towards a stronger
BRET response with the membrane-proximal PDE2-CAMYEL
sensor than the cytosolic CAMYEL sensor suggesting a slightly
higher cAMP increase near the membrane. However, while PDE
inhibition increased the cAMP response, there was no evidence of
a differential effect of inhibiting membrane-associated and
cytosolic PDEs on cAMP measured in either compartment.
Surprisingly, inhibition of PDE3/10 augmented the cAMP
response to 1 mM forskolin, but not that of 10 nM PGE1, while
the opposite was observed for inhibition of PDE4.
Relative importance of different PDEs depends on the
level of stimulation rather than mode of stimulation
The differential modulation by PDE4 and PDE3/10 inhibitors
of the cAMP response to 1 mM forskolin and 10 nM PGE1 may
either reflect a difference in PDE cAMP control of the two modes of
stimulationorbea resultofthestrengthofactivation- 10 nMPGE1
alone gave a 3–4 fold larger increase in BRET response than 1 mM
forskolin. To address this question, we tested a range of forskolin
and PGE1 concentrations in combination with PDE inhibitors. As
in the previous experiment, cAMP was measured both by the
plasma-membraneand incytosol to evaluate if there was differential
regulation of cAMP, dependent on cAMP concentration. Mean 6
SEM relative responses from three independent experiments for
these conditions are shown in Figure 5, while time-resolved absolute
changes in BRET signal are shown in Figure S1 and S2.
As expected, the BRET response increased with increasing
concentrations of forskolin and PGE1. The BRET response to
1 nM PGE1 was comparable to that induced by 1 mM forskolin,
and, in both cases, the PDE4 inhibitor did not significantly
increase the BRET response, while it was increased 2–3 folds by
PDE3/10 inhibitors. Increasing concentrations to 3 nM PGE1
and 2 mM forskolin approximately doubled the BRET response
and changed the impact of PDE inhibition in both cases so both
PDE4 and PDE3/10 inhibitors gave an increase in BRET
response. This trend continued so at even higher levels of stimu-
lation, PDE4 inhibitor robustly increased cAMP response, while
only small or insignificant effects was observed for PDE3/10
inhibitors.
There was a larger response with the membrane-proximal
PDE2-CAMYEL sensor than the cytosolic CAMYEL in 23 out of
24 tested conditions though the difference was only significant for
one of them (4 mM forskolin without PDE inhibitors). Again, no
difference in the time to reach half-maximal BRET response for
the two sensors was observed (results not shown).
In summary, independent of the method of stimulation, PDE3/
10 inhibition predominantly increases cAMP response to adenylyl
cyclase stimulation at low levels of stimulation, while PDE4
inhibition predominantly increases cAMP response at higher levels
of stimulation. The BRET responses with the membrane-proximal
PDE2-CAMYEL sensor are generally slightly stronger than those
of the cytosolic CAMYEL sensor, suggesting a slightly higher
cAMP response near the membrane. There was no evidence for
differential effect of membrane associated PDEs compared to
cytosolic PDEs in the regulation of cAMP in the same areas.
Discussion
In this study, we have measured intracellular cAMP concen-
trations in living HEK293 cells with the BRET sensor CAMYEL
[17] and a novel membrane-targeted variant that we have made
by fusing CAMYEL to the membrane-targeting motif from PDE2.
Responses from differently targeted molecular sensors can only be
directly compared when they are unimolecular and have very
similar or identical cAMP affinity as we have shown for our BRET
sensors. Two previous studies have used such validated sensors in
HEK293 cells. Terrin et al. [13] observed a maximal cAMP
response to 1 mM PGE1 of 31.461.2% with a membrane-targeted
FRET sensor compared to 23.561.4% with a cytosolic sensor,
demonstrating a significantly higher cAMP concentration at the
plasma membrane. DiPilato et al. [12] observed a maximal cAMP
response to 10 mM isoproterenol of 18.361.2% with a membrane-
targeted FRET sensor compared to 16.861.0% with a cytosolic
sensor, a trend to higher cAMP at the plasma membrane. In our
study, most individual comparisons between the cAMP BRET
response at the plasma membrane and in the cytosol were
statistically insignificant. However, the cAMP BRET response at
the plasma membrane was higher than in the cytosol in 23 out of
24 comparisons, which is highly significant. So in accordance with
previous studies using FRET sensors [12,13], our study with
BRET sensors suggests a small gradient of cAMP from the plasma
membrane in stimulated HEK293 cells.
The best supported mechanism for achieving cAMP compart-
mentalization is that the PDEs are compartmentalized as well;
therefore, a detailed analysis of PDE activity in the model system is
critical. In an earlier study of cAMP PDE activity in HEK293B2
cells, PDEs 3, 4B and 4D were found to be major PDEs, but only
PDE3 and PDE4 inhibitors were used in the analysis [20]. The
PDE activity analysis in our study provides additional details by
testing PDE activity in subcellularly fractionated lysates rather
than total lysate and by testing additional selective PDE inhibitors.
We found that PDE10A also contributes to PDE activity in
HEK293 cells and that PDEs 3 and 10 dominate PDE activity in
the membrane fraction while PDE4 is the dominant PDE in the
cytosolic fraction.
Figure 4. Effect of selective PDE inhibitors on cAMP response in HEK293 cells. Changes in BRET signal were measured in HEK293 cells
transfected with either CAMYEL or PDE2-CAMYEL. (A and B) BRET was measured in response to addition of PDE inhibitors. 50 nM roflumilast or
400 nM cilostamide and 300 nM MP-10 was added at time 0. (C–F) BRET was measured in response to stimulation with 1 mM forskolin (C, D) or 10 nM
PGE1 (E, F). Forskolin or PGE1 was added at time 0 alone or in combination with 50 nM roflumilast or 400 nM cilostamide and 300 nM MP-10. For
baselines, buffer was added, and for maximum response, 10 mM forskolin plus all three PDE inhibitors were added. Each point represents the mean 6
SEM of triplicate determinations in a representative experiment. (G and H) Summary of BRET measurements. Relative BRET responses are averaged for
the time period 21–30 min after addition of drugs. The results represent the mean 6 SEM of three experiments. ns (not significant), P.0.05;
*, 0.01,P,0.05; **, 0.001,P,0.01.
doi:10.1371/journal.pone.0024392.g004
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compare the impact of inhibition of the membrane associated
PDEs 3 and 10 to the predominantly cytosolic PDE4 in living cells.
We did not observe any differential effects on cAMP measured
with the cytosolic and the membrane-bound BRET sensor with
either group of inhibitors. The apparent lack of differential
regulation of cAMP by the PDEs was observed both for forskolin
and PGE1 cAMP induction. The sensitivity of the analysis is of
course likely to be limited by the small subcellular differences in
cAMP concentrations observed in the small HEK293 cells.
Furthermore, it should be noted that PDE4 is also present at the
membrane and that the relative contribution of PDEs to cAMP
control may be different in living cells and lysate due to for
example different localization of the PDEs within the membrane
compartment. Our data are in apparent contrast to data obtained
by Terrin et al. [13]: In HEK293 cells stimulated with 1 mM
PGE1, siRNA-mediated knockdown of cytosolic PDE4D was
found to invert the cAMP gradient from membrane to cytosol,
Figure 5. Different PDEs dominate at different cAMP concentrations. Average relative BRET response 21–30 min after addition of forskolin
(A, B) or PGE1 (C, D) in combination with PDE inhibitors to HEK293 cells transfected with CAMYEL or PDE2-CAMYEL. Different concentrations of
forskolin or PGE1 was added alone or in combination with 50 nM roflumilast or 400 nM cilostamide and 300 nM MP-10 as indicated. From curves
similar to those shown in Figure 4, the change in BRET signal was calculated relative to the maximum response (10 mM forskolin plus all three PDE
inhibitors). The results represent the mean 6 SEM of three experiments. ns (not significant), P.0.05; *, 0.01,P,0.05; **, 0.001,P,0.01.
doi:10.1371/journal.pone.0024392.g005
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effect [13]. The apparent discrepancy with our result may be due
to the difference between the acute inhibition with inhibitors and
siRNA-mediated knockdown, which is long-lasting and may lead
to compensatory changes. Supporting a difference between genetic
knockdown and chemical inhibition, they observed no effect on
the cAMP gradient in response to treatment with the PDE4
inhibitor rolipram, while it was abolished when both active PDE4
isoforms PDE4B and PDE4D were knocked down simultaneously
with siRNA [13].
Irrespective of the localization of the cAMP BRET sensor, we
found that PDE3/10 inhibitors more than doubled the BRET
signal in HEK293 cells at low levels of adenylyl cyclase stimula-
tion, but had low or non-significant effects at higher levels of
adenylyl cyclase stimulation. In contrast, the PDE4 inhibitor had
no significant effect on intracellular cAMP concentrations at low
levels of adenylyl cyclase stimulation, while it strongly enhanced
the BRET signal at higher levels of adenylyl cyclase stimulation.
The different subcellular localizations of the PDEs may contribute,
but the different KM of the PDEs is a more likely explanation.
Reported estimates of cAMP KM for PDE3 and PDE10 are 0.15–
0.38 mM [21–23] and 0.05–0.2 mM [24,25], respectively, whereas
it is 1.2–5.2 mM for PDE4, depending on the subtype [26]. The
higher KM of PDE4 means that the relative activity of PDE4 will
increase at higher cAMP concentrations, since the PDE3 and
PDE10 enzymes will saturate faster. The effects of PDE3/10 and
PDE4 inhibitors on intracellular cAMP concentrations as mea-
sured with the BRET sensors are approximately equal at concen-
trations of 2 mM forskolin or 3 nM PGE1. At these concentrations,
the effect of the stimulants alone results in a BRET change of
around 20%, which from the in vitro characterization of the BRET
sensors (Figure 2) can be calculated to correspond to a cAMP
concentration of just over 1 mM. At this cAMP concentration,
total PDE4 activity was found to be similar to total activity of
PDE3 and PDE10.
Although there are some recent reports of other systems where
substrate affinity seems to be critical for determining PDE control
of cAMP [27,28], the influence of the different affinities of PDEs
for cAMP on the control of cAMP concentration in living cells has
not received much attention. The data presented here suggest that
in HEK293 cells, the enzymatic properties of the PDEs are more
important than their subcellular localization in determining their
effect on cAMP concentration at the plasma membrane and in the
cytosol.
Materials and Methods
Reagents
Prostaglandin E1, forskolin, and cilostamide were purchased
from Sigma, BAY 60-7550 was purchased from Alexis, and
Coelenterazine-h from Interchim. MP-10 and roflumilast were
synthesized by H. Lundbeck A/S. The PDE1 inhibitor used in this
study was 5-(4-Diethylamino-benzyl)-1-methyl-3-propyl-1,6-dihy-
dro-pyrazolo[4,3-d]pyrimidin-7-one [29], which was also synthe-
sized by H. Lundbeck A/S.
Cell culture and transfection
HEK293 cells were obtained from American Type Culture
Collection and cultured in Dulbecco’s modified Eagle medium
with GlutaMAX (Invitrogen) supplemented with 10% fetal bovine
serum, 100 U/ml penicillin, and 100 mg/ml streptomycin.
Transfection was done with FuGENE 6 (Roche) according to
the manufacturer’s instructions. Lysis, imaging and BRET
measurements were performed after 24–48 hours.
PDE activity assays
HEK293 cells were lysed in 50 mM Tris buffer, pH 8.0, with
1 mM MgCl2 and 1% Complete protease inhibitor cocktail
(Roche) and separated into cytosol and membrane fraction. After
centrifugation for 30 min at 20,0006 g, the supernatant was
removed and 0.1% Triton X100 added (cytosolic fraction). The
pellet was resuspended in the same buffer, but with 0.5% Triton
X100 added, the centrifugation was repeated, and the supernatant
removed (membrane fraction). PDE activity was measured using a
scintillation proximity assay (SPA)-based method as previously
described [30]. Reported IC50s for PDE inhibitors used (primary
target): 5-(4-Diethylamino-benzyl)-1-methyl-3-propyl-1,6-dihydro-
pyrazolo[4,3-d]pyrimidin-7-one (PDE1), 38 nM [29]; BAY 60-
7550 (PDE2), 4.7 nM [31]; cilostamide (PDE3), 27–50 nM [32];
roflumilast (PDE4), 0.8 nM [33]; MP-10 (PDE10), 0.18 nM [34].
BRET sensor constructs
The BRET sensor CAMYEL (pcDNA3L-His-CAMYEL) was
purchased from ATCC. For generation of the membrane-targeted
variant PDE2-CAMYEL, DNA encoding the N-terminal mem-
brane targeting domain of PDE2A3 (amino acids 1–196) was PCR
amplified using the primer pair 59-GTG CAA GCT TAT GGG
GCA GGC ATG CGG CCA-39 and 59-CGT GTA CAG CTG
CTG CAG GAC CTG CAC C-39 followed by insertion into
pcDNA3L-His-CAMYEL using HindIII and BsrGI.
Subcellular localization of BRET sensor
Western blotting: HEK293 cells transfected with BRET sensor
constructs were harvested, lysed and fractionated into cytosolic
and membrane fractions as described for the PDE activity assays.
The fractions were subjected to denaturing SDS/PAGE on 4–
12% Bis-Tris gel (Invitrogen) and subsequent Western blotting on
polyvinylidene difluoride membranes (Millipore). Rabbit poly-
clonal anti-GFP antibody (Abcam) was used as primary antibody.
Swine anti-rabbit conjugated with horseradish peroxidase
(DAKO) was used as secondary antibody. The blot was developed
using the SuperSignal West Dura kit (Pierce).
Imaging: HEK293 cells that had been transfected with either
BRET sensor construct on glass coverslips were fixated with 4%
paraformaldehyde. Confocal images were acquired on an Eclipse
TE300 microscope (Nikon) equipped with the Bio-Rad Radi-
ance2000 confocal system. Cells were excited using the 488 nm
line of the Krypton/Argon laser for imaging Citrine.
Activation constants of BRET sensors
HEK293 cells expressing CAMYEL or PDE2-CAMYEL were
harvested and lysed in PBS:H2O, 1:2 with 0.5% Triton X100 and
1% Complete protease inhibitor cocktail (Roche). After centrifu-
gation at 20,0006g for 30 min, the supernatant was removed and
the ionic concentrations adjusted towards intracellular levels
(40 mM Hepes, pH 7.2, 140 mM KCl, 10 mM NaCl, 1.5 mM
MgCl2). Coelenterazine-h was added to a final concentration of
5 mM together with different concentrations of cAMP. Emission
from RLuc and Citrine was measured simultaneously at 460 nm
and 535 nm in an EnVision Multilabel Reader (PerkinElmer).
Apparent activation constants were determined by fitting the
obtained data to a sigmoidal dose-response curve (GraphPad
Prism 4).
BRET assays on living cells
HEK293 cells were seeded at 1610
6 cells/well in 6-well plates.
After 24 h, cells were transfected with CAMYEL or PDE2-
CAMYEL. 24 h after transfection, cells in each well were washed
cAMP Control in Two Compartments in HEK293 Cells
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drops of trypsin (0.05% Trypsin/EDTA, Invitrogen), suspended in
1.5 ml HBSS and 80 mL/well were transferred to white 96-well
half area plates (Corning). After 1 h of serum starvation in
incubator, 10 mL coelenterazine-h in HBSS was added to a final
concentration of 5 mM and emission from RLuc and Citrine was
measured simultaneously at 460 nm and 535 nm every minute in
an EnVision Multilabel Reader (PerkinElmer). BRET signal was
calculated as the ratio between emission at 535 nm and emission
at 460 nm. Stimulation was initialized by addition of 10 ml
forskolin/PGE1 and PDE inhibitor(s) diluted in HBSS to 106final
concentration. All experiments included untreated cells and cells
treated with 10 mM forskolin together with PDE3, 4 and 10
inhibitors that was used to estimate and compare maximum
response.
Supporting Information
Figure S1 Changes in cAMP concentration in response
to forskolin. BRET was measured in HEK293 cells transfected
with either CAMYEL or PDE2-CAMYEL. 1 mM (A, B), 2 mM
(C, D), 4 mM (E, F) or 8 mM (G, H) forskolin was added at time 0
alone or in combination with 50 nM roflumilast or 400 nM
cilostamide and 300 nM MP-10. For baselines, buffer was added,
and for maximum response, 10 mM forskolin plus all three PDE
inhibitors were added. Each point represents the mean 6 SEM of
triplicate determinations. Data represents one of three experiments
summarized in Figure 5A and B.
(TIF)
Figure S2 Changes in cAMP concentration in response
to prostaglandin E1. BRET was measured for HEK293 cells
transfected with either CAMYEL or PDE2-CAMYEL. 1 nM (A,
B), 3 nM (C, D), 10 nM (E, F) or 100 nM (G, H) PGE1 was added
at time 0 alone or in combination with 50 nM roflumilast or
400 nM cilostamide and 300 nM MP-10. For baselines, buffer was
added, and for maximum response, 10 mM forskolin plus all three
PDE inhibitors were added. Each point represents the mean 6
SEM of triplicate determinations. Data represents one of three
experiments summarized in Figure 5C and D.
(TIF)
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